Fig. 4
Immunization with hAEC lysate or heterotopic live hAEC vaccination neither conferred protection nor prolonged survival rate in a murine model of colon cancer and melanoma. BALAB/c mice were vaccinated in the right dorsal flank with 1 × 106 hAEC for three times. Seven days after the last vaccination, mice were challenged with 5 × 105 CT26 injected subcutaneously at the counter side of the vaccinations (left dorsal flank) (a). In other settings, BALAB/c mice were immunized twice with either hAEC or CT26 lysates prepared by two different protocols (mechanical solubilization and chemical disruption) in conjunction with CpG 1826 and Poly I:C as adjuvants. C57BL/6 mice received tumor lysate prepared by chemical disruption. Vaccinated mice were challenged with CT26 or B16F10 injected subcutaneously at the same side of the hAEC vaccination. Tumor volumes were regularly monitored and calculated by measuring tumor dimensions (L × W) with digital calipers. In the case of survival rate, mice were considered dead when the tumor surface area exceeded 225 mm2